Plus Therapeutics, Inc.

Stocks

PSTV

US72941H8060

Delayed Nasdaq Other stock markets 14:36:15 2026-07-24 EDT			5-day change	1st Jan Change
3.855 ^USD	+1.98%		+3.07%	-69.90%

07-16	Plus Therapeutics, Inc. And Genomic Testing Cooperative, LCA Partner To Integrate Next-Generation Sequencing Into The CNSide CSF Assay Platform	CI
07-16	Plus Therapeutics, Genomic Testing Cooperative to Integrate NGS Technology Into CNSide CSF Assay Platform	MT

Transcript : Plus Therapeutics, Inc. - Special Call

Published on 01/22/2026 at 11:35 am EST - Modified on 01/23/2026 at 02:36 pm EST

S&P Capital IQ

Add MarketScreener to your sources

Presentation Operator Message
Operator (Operator)

Good day, and welcome to the Plus Therapeutics January 22, 2026, Business Update Conference Call. [Operator Instructions] Please note that this event

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Plus Therapeutics, Inc.

07-16	Plus Therapeutics, Inc. And Genomic Testing Cooperative, LCA Partner To Integrate Next-Generation Sequencing Into The CNSide CSF Assay Platform	CI
07-16	Plus Therapeutics, Genomic Testing Cooperative to Integrate NGS Technology Into CNSide CSF Assay Platform	MT
07-14	Plus Therapeutics, Inc. Highlights Updated NCCN CNS Cancers Guidelines and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring	CI
06-30	Plus Therapeutics, Inc. - Special Call
06-30	Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress	CI
06-29	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell 3000E Index	CI
06-28	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell 3000E Growth Benchmark	CI
06-28	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell Microcap Growth Benchmark Index	CI
06-28	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell Microcap Index	CI
06-25	Plus Therapeutics Unit Signs Coverage Agreement With Elevance Health for CNSide Assay	MT
05-26	Plus Therapeutics Presents Health Economics Study Demonstrating Substantial Healthcare Cost Reduction with CNSide Diagnostic Platform	CI
05-19	Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology	CI
05-15	Plus Therapeutics Q1 Loss Narrows, Revenue Declines	MT
05-15	Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Plus Therapeutics announces oral presentation highlighting Reyobiq(TM) clinical and translational data demonstrating favorable safety, survival, and emerging immunomodulation in leptomeningeal metastases	RE